TruBridge (TBRG) 10-Q 9 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	000-49796
Entity Registrant Name	COMPUTER PROGRAMS AND SYSTEMS, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	74-3032373
Entity Address, Address Line One	54 St. Emanuel Street
Entity Address, City or Town	Mobile
Entity Address, State or Province	AL
Entity Address, Postal Zip Code	36602
City Area Code	251
Local Phone Number	639-8100
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	CPSI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		14,648,442
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Central Index Key	0001169445
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 17,114	$ 12,671
Accounts receivable (net of allowance for expected credit losses of $1,604 and $1,701, respectively)	30,542	32,414
Financing receivables, current portion, net (net of allowance for expected credit losses of $364 and $541, respectively)	7,277	10,821
Inventories	1,151	1,084
Prepaid income taxes	4,056	1,789
Prepaid expenses and other	10,837	8,365
Total current assets	70,977	67,144
Property and equipment, net	12,100	13,139
Software development costs, net	9,130	3,210
Operating lease assets	7,424	6,610
Financing receivables, net of current portion (net of allowance for expected credit losses of $465 and $948, respectively)	8,471	11,477
Other assets, net of current portion	3,209	2,787
Intangible assets, net	98,875	71,689
Goodwill	177,196	150,216
Total assets	387,382	326,272
Current liabilities:
Accounts payable	5,454	7,716
Current portion of long-term debt	3,926	3,457
Deferred revenue	10,844	8,130
Accrued vacation	5,145	5,353
Other accrued liabilities	16,245	12,786
Total current liabilities	41,614	37,442
Long-term debt, net of current portion	111,298	73,360
Operating lease liabilities, net of current portion	5,800	5,092
Deferred tax liabilities	12,684	10,378
Total liabilities	171,396	126,272
Stockholders’ equity:
Common stock, $0.001 par value; 30,000 shares authorized; 14,734 and 14,511 shares issued and outstanding, respectively	15	15
Additional paid-in capital	185,801	181,622
Retained earnings	32,653	19,624
Treasury stock, 86 shares and 47 shares, respectively	(2,483)	(1,261)
Total stockholders’ equity	215,986	200,000
Total liabilities and stockholders’ equity	$ 387,382	$ 326,272

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$ 1,604	$ 1,701
Financing receivable, allowance for credit loss, current	364	541
Financing receivable, allowance for credit loss, noncurrent	$ 465	$ 948
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	30,000,000	30,000,000
Common stock, shares issued (in shares)	14,734,000	14,511,000
Common stock, shares outstanding (in shares)	14,734,000	14,511,000
Treasury stock, shares (in shares)	86,000	47,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Sales revenues:
Total sales revenues	$ 70,091	$ 68,333	$ 206,629	$ 197,639
Costs of sales:
Total costs of sales	34,802	32,915	102,599	96,001
Gross profit	35,289	35,418	104,030	101,638
Operating expenses:
Product development	7,700	8,549	22,598	25,190
Sales and marketing	5,200	6,359	15,813	18,526
General and administrative	14,184	11,440	38,322	34,242
Amortization of acquisition-related intangibles	3,674	2,866	10,114	8,599
Total operating expenses	30,758	29,214	86,847	86,557
Operating income	4,531	6,204	17,183	15,081
Other income (expense):
Other income	123	916	1,160	1,241
Loss on extinguishment of debt	0	0	0	(202)
Interest expense	(825)	(850)	(2,249)	(2,832)
Total other income (expense)	(702)	66	(1,089)	(1,793)
Income before taxes	3,829	6,270	16,094	13,288
Provision for income taxes	1,085	1,002	3,065	2,165
Net income	$ 2,744	$ 5,268	$ 13,029	$ 11,123
Net income per common share-basic (in dollars per share)	$ 0.19	$ 0.36	$ 0.89	$ 0.77
Net income per common share-diluted (in dollars per share)	$ 0.19	$ 0.36	$ 0.89	$ 0.77
Weighted average shares outstanding used in per common share computations:
Basic (in shares)	14,334	14,095	14,276	14,022
Diluted (in shares)	14,343	14,095	14,303	14,022
Dividends declared per common share (in dollars per share)	$ 0	$ 0.10	$ 0	$ 0.30
System sales and support
Sales revenues:
Total sales revenues	$ 35,560	$ 40,388	$ 107,893	$ 116,297
Costs of sales:
Total costs of sales	17,425	17,628	52,250	51,901
TruBridge
Sales revenues:
Total sales revenues	34,531	27,945	98,736	81,342
Costs of sales:
Total costs of sales	$ 17,377	$ 15,287	$ 50,349	$ 44,100

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in-Capital	Retained Earnings	Treasury Stock
Beginning Balance (in shares) at Dec. 31, 2019		14,356
Beginning Balance at Dec. 31, 2019	$ 184,347	$ 14	$ 174,618	$ 9,715	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	11,123			11,123
Issuance of restricted stock (in shares)		156
Issuance of restricted stock		$ 1	(1)
Stock-based compensation	5,174		5,174
Dividends	(4,338)			(4,338)
Ending Balance (in shares) at Sep. 30, 2020		14,512
Ending Balance at Sep. 30, 2020	196,306	$ 15	179,791	16,500	0
Beginning Balance (in shares) at Jun. 30, 2020		14,512
Beginning Balance at Jun. 30, 2020	190,925	$ 15	178,227	12,683	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	5,268			5,268
Stock-based compensation	1,564		1,564
Dividends	(1,451)			(1,451)
Ending Balance (in shares) at Sep. 30, 2020		14,512
Ending Balance at Sep. 30, 2020	196,306	$ 15	179,791	16,500	0
Beginning Balance (in shares) at Dec. 31, 2020		14,511
Beginning Balance at Dec. 31, 2020	200,000	$ 15	181,622	19,624	(1,261)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	13,029			13,029
Issuance of restricted stock (in shares)		229
Forfeiture of common stock (in shares)		(6)
Stock-based compensation	4,179		4,179
Treasury stock acquired	(1,222)				(1,222)
Ending Balance (in shares) at Sep. 30, 2021		14,734
Ending Balance at Sep. 30, 2021	215,986	$ 15	185,801	32,653	(2,483)
Beginning Balance (in shares) at Jun. 30, 2021		14,734
Beginning Balance at Jun. 30, 2021	211,542	$ 15	184,101	29,909	(2,483)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,744			2,744
Stock-based compensation	1,700		1,700
Ending Balance (in shares) at Sep. 30, 2021		14,734
Ending Balance at Sep. 30, 2021	$ 215,986	$ 15	$ 185,801	$ 32,653	$ (2,483)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating Activities:
Net income	$ 13,029	$ 11,123
Adjustments to net income:
Provision for credit losses	2,080	2,695
Deferred taxes	2,306	1,060
Stock-based compensation	4,179	5,174
Depreciation	1,641	1,334
Amortization of acquisition-related intangibles	10,114	8,599
Amortization of software development costs	527	79
Amortization of deferred finance costs	220	242
Loss on extinguishment of debt	0	202
Loss on disposal of PP&E	313	0
Changes in operating assets and liabilities:
Accounts receivable	1,304	3,490
Financing receivables	5,962	2,701
Inventories	(67)	136
Prepaid expenses and other	(2,892)	(1,765)
Accounts payable	(2,723)	(817)
Deferred revenue	1,414	(1,174)
Other liabilities	(666)	553
Prepaid income taxes	(2,267)	(651)
Net cash provided by operating activities	34,474	32,981
Investing Activities:
Purchase of business, net of cash acquired	(59,634)	0
Investment in software development	(6,447)	(2,356)
Purchase of property and equipment	(915)	(3,241)
Net cash used in investing activities	(66,996)	(5,597)
Financing Activities:
Dividends paid	0	(4,338)
Proceeds from long-term debt	0	67
Payments of long-term debt principal	(2,813)	(3,132)
Proceeds from revolving line of credit	61,000	0
Payments of revolving line of credit	(20,000)	(15,561)
Treasury stock purchases	(1,222)	0
Net cash provided by (used in) financing activities	36,965	(22,964)
Increase in cash and cash equivalents	4,443	4,420
Cash and cash equivalents at beginning of period	12,671	7,357
Cash and cash equivalents at end of period	17,114	11,777
Supplemental disclosure of cash flow information:
Cash paid for interest	1,979	2,588
Cash paid for income taxes, net of refund	$ 3,116	$ 1,756

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") and include all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are considered of a normal recurring nature. Quarterly results of operations are not necessarily indicative of annual results. Certain footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2020 was derived from the audited consolidated balance sheet at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of Computer Programs and Systems, Inc. ("CPSI" or the "Company") for the year ended December 31, 2020 and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. During the second quarter of 2021, we elected to change our method of estimating the labor costs incurred in developing software assets requiring capitalization under Accounting Standards Codification ("ASC") 350-40, Internal Use Software. Prior to this change, we estimated the associated labor costs using an estimated time-equivalent for workload metrics commonly utilized within agile software development environments. With this change, we now estimate these labor costs using the distribution of these agile workload metrics between capitalizable and non-capitalizable units of work. We believe this change is preferable as the new methodology better estimates capitalizable labor costs and is consistent with industry best practices. We have determined that this change is a change in accounting estimate effected by a change in accounting principle and, as such, has been accounted for on a prospective basis. See Note 6, “Software Development,” for further information. Principles of Consolidation The condensed consolidated financial statements of CPSI include the accounts of TruBridge, LLC ("TruBridge"), Evident, LLC ("Evident"), Healthland Holding Inc. ("HHI"), iNetXperts, Corp. d/b/a Get Real Health ("Get Real Health"), and TruCode LLC (TruCode), all of which are wholly-owned subsidiaries of CPSI. The accounts of HHI include those of its wholly-owned subsidiaries, Healthland Inc. ("Healthland"), Rycan Technologies, Inc. ("Rycan"), and American HealthTech, Inc. ("AHT"). All significant intercompany balances and transactions have been eliminated.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2021
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Standards Adopted in 2021 There were no new accounting standards required to be adopted in 2021 that would have a material impact on our consolidated financial statements. New Accounting Standards Yet to be Adopted We do not believe that any other recently issued but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

REVENUE RECOGNITION

REVENUE RECOGNITION	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION Revenue is recognized upon transfer of control of promised products or services to clients in an amount that reflects the consideration we expect to receive in exchange for those products and services. We enter into contracts that can include various combinations of products and services, which are generally distinct and accounted for as separate performance obligations. The Company employs the 5-step revenue recognition model under ASC 606, Revenue from Contracts with Customers , to: (1) identify the contract with the client, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Revenue is recognized net of shipping charges and any taxes collected from clients, which are subsequently remitted to governmental authorities. System Sales and Support The Company enters into contractual obligations to sell perpetual software licenses, installation, conversion, training, hardware and software application support and hardware maintenance services to acute care community hospitals and post-acute care providers. Non-recurring Revenues • Perpetual software licenses, installation, conversion, and related training are not considered separate and distinct performance obligations due to the proprietary nature of our software and are, therefore, accounted for as a single performance obligation on a module-by-module basis. Revenue is recognized as each module's implementation is completed based on the module's stand-alone selling price ("SSP"), net of discounts. Fees for licenses, installation, conversion, and related training are typically due in three installments: (1) at placement of order, (2) upon installation of software and commencement of training, and (3) upon satisfactory completion of monthly accounting cycle or end-of-month operation by application and as applicable for each application. Often, short-term and/or long-term financing arrangements are provided for software implementations; refer to Note 11 - Financing Receivables for further information. Electronic health records ("EHR") implementations include a system warranty that terminates thirty days from the software go-live date, the date on which the client begins using the system in a live environment. • Hardware revenue is recognized separately from software licenses at the point in time it is delivered to the client. The SSP of hardware is cost plus a reasonable margin. Payment is generally due upon delivery of the hardware to the client. Standard manufacturer warranties apply to hardware. Recurring Revenues • Software application support and hardware maintenance services sold with software licenses and hardware are separate and distinct performance obligations. Revenue for support and maintenance services is recognized based on SSP, which is the renewal price, ratably over the life of the contract, which is generally three • Subscriptions to third party content revenue is recognized as a separate performance obligation ratably over the subscription term based on SSP, which is cost plus a reasonable margin. Payment is due monthly for subscriptions to third party content. • Software as a Service ("SaaS") arrangements for EHR software and related conversion and training services are considered a single performance obligation. Revenue is recognized on a monthly basis as the SaaS service is provided to the client over the contract term. Payment is due monthly for SaaS services provided. Refer to Note 17 - Segment Reporting, for further information, including revenue by client base (acute care or post-acute care) bifurcated by recurring and non-recurring revenue. TruBridge TruBridge provides an array of business processing services ("BPS") consisting of accounts receivable management, private pay services, insurance services, medical coding, electronic billing, statement processing, payroll processing, and contract management. Fees are recognized over the period of the client contractual relationship as the services are performed based on the SSP, net of discounts. Fees for many of these services are invoiced, and revenue recognized accordingly, based on the volume of transactions or a percentage of client accounts receivable collections. Payment is due monthly for BPS with certain amounts varying based on utilization and/or volumes. TruBridge also provides professional IT services. Revenue from professional IT services is recognized as the services are performed based on SSP. Payment is due monthly as services are performed. Deferred Revenue Deferred revenue represents amounts invoiced to clients for which the services under contract have not been completed and revenue has not been recognized, including annual renewals of certain software subscriptions and customer deposits for implementations to be performed at a later date. Revenue is recognized ratably over the life of the software subscriptions as services are provided and at the point-in-time when implementations have been completed. The following table details deferred revenue for the nine months ended September 30, 2021 and 2020, included in the condensed consolidated balance sheets: (In thousands) Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Beginning balance $ 8,130 $ 8,628 Deferred revenue recorded 16,886 13,633 Deferred revenue acquired 1,300 — Less deferred revenue recognized as revenue (15,472) (14,807) Ending balance $ 10,844 $ 7,454 The deferred revenue recorded during the nine months ended September 30, 2021 is comprised primarily of the annual renewals of certain software subscriptions billed during the first quarter of each year and deposits collected for future EHR installations. The deferred revenue recognized as revenue during the nine months ended September 30, 2021 and 2020 is comprised primarily of the periodic recognition of annual renewals that were deferred until earned and deposits for future EHR installations that were deferred until earned. Costs to Obtain and Fulfill a Contract with a Customer Costs to obtain a contract include the commission costs related to SaaS licensing agreements, which are capitalized and amortized ratably over the expected life of the customer. As a practical expedient, we generally recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset would have been one year or less, with the exception of commissions generated from TruBridge sales. TruBridge commissions, which are paid up to twelve months in advance of services performed, are capitalized and amortized over the prepayment period. Costs to obtain a contract are expensed within sales and marketing expenses in the accompanying condensed consolidated statements of income. Contract fulfillment costs related to the implementation of SaaS arrangements are capitalized and amortized ratably over the expected life of the customer. Costs to fulfill contracts consist of the payroll costs for the implementation of SaaS arrangements, including time for training, conversion and installation that is necessary for the software to be utilized. Contract fulfillment costs are expensed within the caption "System sales and support - Cost of sales" in the accompanying condensed consolidated statements of income. Costs to obtain and fulfill contracts related to SaaS arrangements are included within the "Prepaid expenses and other" and "Other assets, net of current portion" line items on our condensed consolidated balance sheets. The following table details costs to obtain and fulfill contracts with customers for the nine months ended September 30, 2021 and 2020, included in the condensed consolidated balance sheets: (In thousands) Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Beginning balance $ 5,992 $ 4,440 Costs to obtain and fulfill contracts capitalized 4,719 4,839 Less costs to obtain and fulfill contracts recognized as expense (4,441) (4,044) Ending balance $ 6,270 $ 5,235 Remaining Performance Obligations Disclosures regarding remaining performance obligations are not considered material as the overwhelming majority of the Company's remaining performance obligations either (a) are related to contracts with an expected duration of one year or less, or (b) exhibit revenue recognition in the amount to which the Company has the right to invoice.

BUSINESS COMBINATION

BUSINESS COMBINATION	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
BUSINESS COMBINATION	BUSINESS COMBINATION Acquisition of TruCode On May 12, 2021, we acquired all of the assets and liabilities of TruCode LLC, a Virginia limited liability company (“TruCode”), pursuant to a Stock Purchase Agreement dated May 12, 2021. Based in Alpharetta, Georgia, TruCode provides configurable, knowledge-based software that gives coders, clinical documentation improvement specialists and auditors the flexibility to code according to their knowledge, preferences and experience. The cloud-based medical coding solution will be bundled with the TruBridge solutions and services to enhance revenue cycle performance for healthcare organizations of all sizes. Consideration for the acquisition included cash (net of cash of the acquired entity) of $59.6 million (inclusive of sellers' transaction expenses), plus a contingent earnout payment of up to $15.0 million tied to TruCode's earnings before interest, tax, depreciation, and amortization ("EBITDA") (subject to certain pro-forma adjustments) for the twelve-month period concluding on the anniversary date of the acquisition. During 2021, we have incurred approximately $0.9 million of pre-tax acquisition costs in connection with the acquisition of TruCode. Acquisition costs are included in general and administrative expenses in our consolidated statements of income. Our acquisition of TruCode will be treated as a purchase in accordance with ASC 805, Business Combinations , which requires allocation of the purchase price to the estimated fair values of assets and liabilities acquired in the transaction. Our allocation of the purchase price is based on management's judgment after evaluating several factors, including a preliminary valuation assessment. The allocation is preliminary and subject to changes, which could be significant, as additional information becomes available and appraisals of intangible assets and deferred tax positions are finalized. The preliminary allocation of the purchase price paid for TruCode as of September 30, 2021 was as follows: (In thousands) Purchase Price Allocation Acquired cash $ 4,249 Accounts receivable 924 Prepaid expenses 2 Intangible assets 37,300 Goodwill 26,980 Accounts payable and accrued liabilities (1,772) Contingent consideration (2,500) Deferred revenue (1,300) Net assets acquired $ 63,883 The intangible assets in the table above are being amortized on a straight-line basis over their estimated useful lives. The amortization is included in amortization of acquisition-related intangibles in our condensed consolidated statements of income. The fair value measurements of tangible and intangible assets and liabilities were based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value measurement hierarchy (see Note 16 - Fair Value). Level 3 inputs included, among others, discount rates that we estimated would be used by a market participant in valuing these assets and liabilities, projections of revenues and cash flows, client attrition rates and market comparables. Our condensed consolidated statement of operations for the three and nine months ended September 30, 2021 includes revenues of approximately $2.6 million and $4.1 million, respectively, and pre-tax net income of approximately $1.4 million and $1.8 million, respectively, attributed to the acquired business since the May 12, 2021 acquisition date. The following unaudited pro forma revenue, net income and earnings per share amounts for the three and nine months ended September 30, 2021 and 2020 give effect to the TruCode acquisition as if it had been completed on January 1, 2020. The pro forma financial information is presented for illustrative purposes only and is not necessarily indicative of what the operating results actually would have been during the periods presented had the TruCode acquisition been completed during the periods presented. In addition, the unaudited pro forma financial information does not purport to project future operating results. The pro forma information does not fully reflect: (1) any anticipated synergies (or costs to achieve synergies) or (2) the impact of non-recurring items directly related to the TruCode acquisition. Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share data) 2021 2020 2021 2020 Pro forma revenues $ 70,478 $ 71,177 $ 212,449 $ 205,732 Pro forma net income $ 3,115 $ 5,378 $ 15,060 $ 11,181 Pro forma diluted earnings per share $ 0.22 $ 0.37 $ 1.03 $ 0.76

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	PROPERTY AND EQUIPMENT Property and equipment, net was comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Land $ 2,848 $ 2,848 Buildings and improvements 8,269 8,242 Computer equipment 7,863 7,144 Leasehold improvements 783 1,283 Office furniture and fixtures 682 829 Automobiles 18 18 Property and equipment, gross 20,463 20,364 Less: accumulated depreciation (8,363) (7,225) Property and equipment, net $ 12,100 $ 13,139

SOFTWARE DEVELOPMENT

SOFTWARE DEVELOPMENT	9 Months Ended
	Sep. 30, 2021
Research and Development [Abstract]
SOFTWARE DEVELOPMENT	SOFTWARE DEVELOPMENT Software development costs are accounted for in accordance with ASC 350-40, Internal-Use Software. We capitalize incurred labor costs for software development from the time the preliminary project phase is completed until the software is available for general release. Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its value on a straight-line basis over that estimated life, which is estimated to be five years. We evaluate capitalized software development costs for impairment when there is an indication that the useful life has changed or that the unamortized costs may not be recoverable. A write-down of the value of the asset may be recorded as a charge to earnings. Upon the software's availability for general release, we commence amortization of the capitalized software costs on a module-by-module basis. During the second quarter of 2021, our ongoing monitoring activities associated with the capitalization of software development costs and the related correlation between capitalization rates and operational metrics designed to reflect the distribution of work revealed that our then-current labor capitalization methodology did not fully reflect all of the critical activities necessary to develop software assets. Consequently, during the second quarter of 2021, we elected to change our method of estimating the labor costs incurred in developing software assets. Prior to this change, we estimated the associated labor costs using an estimated time-equivalent for workload metrics commonly utilized within agile software development environments. With this change, we now estimate these labor costs using the distribution of these agile workload metrics between capitalizable and non-capitalizable units of work. We believe this change is preferable as the new methodology better estimates capitalizable labor costs and is consistent with industry best practices. We have determined that this change in accounting for software development costs is a change in accounting estimate effected by a change in accounting principle and, as such, has been accounted for on a prospective basis. In connection with this change, we capitalized software development costs of $2.4 million and $6.5 million during the three and nine months ended September 30, 2021, respectively. We estimate that the effect of this change was to increase capitalized amounts by approximately $1.1 million and $3.0 million for the three and nine months ended September 30, 2021, respectively, with a corresponding decrease to product development costs. Software development costs, net was comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Software development costs $ 9,774 $ 3,328 Less: accumulated amortization (644) (118) Software development costs, net $ 9,130 $ 3,210

OTHER ACCRUED LIABILITIES

OTHER ACCRUED LIABILITIES	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
OTHER ACCRUED LIABILITIES	OTHER ACCRUED LIABILITIES Other accrued liabilities was comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Salaries and benefits $ 7,364 $ 7,876 Severance 506 25 Commissions 875 1,040 Self-insurance reserves 1,730 1,776 Contingent consideration 2,500 — Other 1,646 551 Operating lease liabilities, current portion 1,624 1,518 Other accrued liabilities $ 16,245 $ 12,786

NET INCOME PER SHARE

NET INCOME PER SHARE	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NET INCOME PER SHARE The Company presents basic and diluted earnings per share ("EPS") data for its common stock. Basic EPS is calculated by dividing the net income attributable to stockholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is determined by adjusting the net income attributable to stockholders of the Company and the weighted average number of shares of common stock outstanding during the period for the effects of all dilutive potential common shares, including awards under stock-based compensation arrangements. The Company's unvested restricted stock awards (see Note 10) are considered participating securities under ASC 260, Earnings Per Share , because they entitle holders to non-forfeitable rights to dividends until the awards vest or are forfeited. When a company has a security that qualifies as a "participating security," the Codification requires the use of the two-class method when computing basic EPS. The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net income to allocate to common stockholders, income is allocated to both common stock and participating securities based on their respective weighted average shares outstanding for the period, with net income attributable to common stockholders ultimately equaling net income less net income attributable to participating securities. Diluted EPS for the Company's common stock is computed using the more dilutive of the two-class method or the treasury stock method. The following is a calculation of the basic and diluted EPS for the Company's common stock, including a reconciliation between net income and net income attributable to common stockholders: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share data) 2021 2020 2021 2020 Net income $ 2,744 $ 5,268 $ 13,029 $ 11,123 Less: Net income attributable to participating securities (59) (151) (293) (338) Net income attributable to common stockholders $ 2,685 $ 5,117 $ 12,736 $ 10,785 Weighted average shares outstanding used in basic per common share computations 14,334 14,095 14,276 14,022 Add: Dilutive potential common shares 9 — 27 — Weighted average shares outstanding used in diluted per common share computations 14,343 14,095 14,303 14,022 Basic EPS $ 0.19 $ 0.36 $ 0.89 $ 0.77 Diluted EPS $ 0.19 $ 0.36 $ 0.89 $ 0.77 During 2019, 2020, and 2021, performance share awards were granted to certain executive officers and key employees of the Company that will result in the issuance of common stock if the predefined performance criteria are met. The awards provide for an aggregate target of 249,952 shares, of which 8,897 and 26,601 have been included in the calculation of diluted EPS for the three and nine months ended September 30, 2021, respectively. The remaining shares have been excluded from the calculation of diluted EPS because the related threshold award performance levels have not been achieved as of September 30, 2021. See Note 10 - Stock-Based Compensation and Equity for more information.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company determines the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment. Our effective tax rate for the three months ended September 30, 2021 increased to an expense of 28.3% from an expense of 16.0% for the three months ended September 30, 2020, due primarily to changes in the Company's periodic provision-to-return adjustments. Such adjustments increased our effective tax rate by 6.1% during the third quarter of 2021 and benefited our effective tax rate by 3.7% during the third quarter of 2020. Our effective tax rate for the nine months ended September 30, 2021 increased to 19.0% from 16.3% for the nine months ended September 30, 2020, primarily due to decreased expectations related to expenditures qualifying for research and development ("R&D") tax credits.

STOCK-BASED COMPENSATION AND EQ

STOCK-BASED COMPENSATION AND EQUITY	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION AND EQUITY	STOCK-BASED COMPENSATION AND EQUITYStock-based compensation expense is measured at the grant date based on the fair value of the award, and is recognized as an expense over the employee's or non-employee director's requisite service period. The following table details total stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020, included in the condensed consolidated statements of income: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2021 2020 2021 2020 Costs of sales $ 311 $ 321 $ 793 $ 1,100 Operating expenses 1,389 1,243 3,386 4,074 Pre-tax stock-based compensation expense 1,700 1,564 4,179 5,174 Less: income tax effect (374) (344) (919) (1,138) Net stock-based compensation expense $ 1,326 $ 1,220 $ 3,260 $ 4,036 The Company's stock-based compensation awards are in the form of restricted stock and performance share awards granted pursuant to the Company's Amended and Restated 2014 Incentive Plan and 2019 Incentive Plan, as amended (the "Plans"). As of September 30, 2021, th ere was $9.0 million of unrecognized compensation expense related to unvested stock-based compensation arrangements granted under the Plans, which is expected to be recognized over a weighted-average period of 2.1 years. Restricted Stock The Company grants restricted stock to executive officers, certain key employees and non-employee directors under the Plans with the fair value of the awards representing the fair value of the common stock on the date the restricted stock is granted. Shares of restricted stock generally vest in equal annual installments over the applicable vesting period, which ranges from one A summary of restricted stock activity (including shares of restricted stock issued pursuant to the settlement of performance share awards) under the Plans during the nine months ended September 30, 2021 and 2020 is as follows: Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Shares Weighted-Average Shares Weighted-Average Unvested restricted stock outstanding at beginning of period 412,967 $ 28.87 525,859 $ 30.51 Granted 153,700 31.22 136,771 26.16 Performance share awards settled through the issuance of restricted stock — — 19,678 30.15 Vested (245,455) 29.16 (265,518) 30.85 Forfeited (6,329) 29.10 — — Unvested restricted stock outstanding at end of period 314,883 $ 29.79 416,790 $ 28.85 Performance Share Awards The Company granted performance share awards to executive officers and certain key employees under the Amended and Restated 2014 Incentive Plan prior to 2019 and under the 2019 Incentive Plan, as amended, beginning in 2019. The number of shares of common stock earned and issuable under each award is determined at the end of a one-year or three-year performance period, based on the Company's achievement of performance goals predetermined by the Compensation Committee of the Board of Directors at the time of grant. The three-year performance share awards include a modifier to the total number of shares earned based on the Company's total shareholder return ("TSR") compared to an industry index. If certain levels of the performance objective are met, the award results in the issuance of shares of restricted stock or common stock corresponding to such level. One-year performance share awards are then subject to time-based vesting pursuant to which the shares of restricted stock vest in equal annual installments over the applicable vesting period, which is generally three years. Three-year performance share awards that result in the issuance of shares of common stock are not subject to time-based vesting at the conclusion of the three-year performance period. In the event that the Company's financial performance meets the predetermined targets for the performance objectives of the one-year and three-year performance share awards, the Company will issue each award recipient the number of shares of restricted stock or common stock, as applicable, equal to the target award specified in the individual's underlying performance share award agreement. In the event the financial results of the Company exceed the predetermined targets, additional shares up to the maximum award may be issued. In the event the financial results of the Company fall below the predetermined targets, a reduced number of shares may be issued. If the financial results of the Company fall below the threshold performance levels, no shares will be issued. The total number of shares issued for the three-year performance share award may be increased, decreased, or unchanged based on the TSR modifier described above. The recipients of performance share awards do not receive dividends or possess voting rights during the performance period and, accordingly, the fair value of the one-year and three-year performance share awards is the quoted market value of CPSI's common stock on the grant date less the present value of the expected dividends not received during the relevant period. The TSR modifier applicable to the three-year performance share awards is considered a market condition and therefore is reflected in the grant date fair value of the award. A Monte Carlo simulation has been used to account for this market condition in the grant date fair value of the award. Expense of one-year performance share awards is recognized using the accelerated attribution (graded vesting) method over the period beginning on the date the Company determines that it is probable that the performance criteria will be achieved and ending on the last day of the vesting period for the restricted stock issued in satisfaction of such awards. Expense of three-year performance share awards is recognized using ratable straight-line amortization over the three-year performance period. In the event the Company determines it is no longer probable that the minimum performance level will be achieved, all previously recognized compensation expense related to the applicable awards is reversed in the period such a determination is made. A summary of performance share award activity under the Plans during the nine months ended September 30, 2021 and 2020 is as follows, based on the target award amounts set forth in the performance share award agreements: Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Shares Weighted-Average Shares Weighted-Average Performance share awards outstanding at beginning of period 252,852 $ 29.27 200,709 $ 30.75 Granted 93,444 31.26 107,298 26.96 Adjusted for actual performance, net of forfeitures (20,373) 29.92 (35,477) 30.15 Performance share awards settled through the issuance of restricted stock — — (19,678) 30.15 Vested (75,971) 30.50 — — Performance share awards outstanding at end of period 249,952 $ 29.59 252,852 $ 29.27 Stock Repurchases On September 4, 2020, our Board of Directors approved a stock repurchase program under which we may repurchase up to $30.0 million of our common stock through September 3, 2022. We repurchased 17,387 shares during the nine months ended September 30, 2021 and no shares during the nine months ended September 30, 2020. The approximate dollar value of shares that may yet be repurchased under the stock repurchase program was $28.2 million as of September 30, 2021. Any future stock repurchase transactions may be made through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. Any repurchase activity will depend on many factors, such as the availability of shares of our common stock, general market conditions, the trading price of our common stock, alternative uses for capital, the Company’s financial performance, compliance with the terms of our Amended and Restated Credit Agreement and other factors. Concurrent with the authorization of this stock repurchase program, the Board of Directors opted to indefinitely suspend all quarterly dividends. In addition to shares repurchased under the approved stock repurchase program, we purchased 21,444 shares during the nine months ended September 30, 2021 to fund required tax withholdings related to the vesting of restricted stock. Shares withheld to cover required tax withholdings related to the vesting of restricted stock do not reduce our total share repurchase authority.

FINANCING RECEIVABLES

FINANCING RECEIVABLES	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
FINANCING RECEIVABLES	FINANCING RECEIVABLES Short-Term Payment Plans The Company provides fixed monthly payment arrangements ("short-term payment plans") over terms ranging from three (In thousands) September 30, December 31, 2020 Short-term payment plans, gross $ 225 $ 1,973 Less: allowance for losses (11) (99) Short-term payment plans, net $ 214 $ 1,874 The significant decrease in short-term payment plan balances during the nine months ended September 30, 2021 is primarily the result of a small number of customer receivables existing as of December 31, 2020 that have since been fully collected or otherwise satisfied. This decrease is not indicative of any underlying trends within our business, and merely reflect customary negotiations and subsequent collections of certain customer balances. Long-Term Financing Arrangements Additionally, the Company provides financing for purchases of its information and patient care systems to certain healthcare providers under long-term financing arrangements expiring in various years through 2026. Under long-term financing arrangements, the transaction price is adjusted by a discount rate that reflects market conditions that would be used for a separate financing transaction between the Company and licensee at contract inception, and takes into account the credit characteristics of the licensee and market interest rates as of the date of the agreement. As such, the amount of fixed fee revenue recognized at the beginning of the license term will be reduced by the calculated financing component. As payments are received from the licensee, the Company recognizes a portion of the financing component as interest income, reported as other income in the condensed consolidated statements of income. These receivables typically have terms from two The significant decrease in long-term financing arrangement balances during the nine months ended September 30, 2021is primarily a result of evolving customer licensing preferences coupled with collections of previously outstanding amounts. Historically, perpetual licenses were the predominant licensing model for new Acute Care EHR customer installations, comprising approximately 75% of such installations during 2016. Customers acquiring our technology solutions under this licensing model frequently opted for our long-term self-financing option, giving rise to a significant accumulation of long-term financing arrangement balances in prior periods. During the intervening years, this customer license preference has shifted dramatically towards SaaS arrangements, which accounted for approximately 70% of 2020 new Acute Care EHR installations and approximately 60% of such activity during the nine months ended September 30, 2021. By nature of the revenue recognition requirements for SaaS arrangements coupled with recurring monthly payments, these arrangements do not give rise to long-term financing arrangements. The components of these receivables were as follows at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Long-term financing arrangements, gross $ 17,952 $ 24,082 Less: allowance for expected credit losses (818) (1,390) Less: unearned income (1,600) (2,268) Long-term financing arrangements, net $ 15,534 $ 20,424 Future minimum payments to be received subsequent to September 30, 2021 are as follows: (In thousands) Years Ending December 31, 2021 $ 4,542 2022 6,013 2023 3,924 2024 2,393 2025 948 Thereafter 132 Total minimum payments to be received 17,952 Less: allowance for expected credit losses (818) Less: unearned income (1,600) Receivables, net $ 15,534 Credit Quality of Financing Receivables and Allowance for Expected Credit Losses The following table is a roll-forward of the allowance for expected credit losses for the nine months ended September 30, 2021 and year ended December 31, 2020: (In thousands) Balance at Beginning of Period Provision Charge-offs Recoveries Balance at End of Period September 30, 2021 $ 1,489 $ 588 $ (1,248) $ — $ 829 December 31, 2020 $ 2,971 $ 1,632 $ (3,114) $ — $ 1,489 The Company’s financing receivables are comprised of a single portfolio segment, as the balances are all derived from short-term payment plan arrangements and long-term financing arrangements within our target market of community hospitals. The Company evaluates the credit quality of its financing receivables based on a combination of factors, including, but not limited to, customer collection experience, current and future economic conditions, the customer’s financial condition, and known risk characteristics impacting the respective customer base of community hospitals, the most notable of which relate to enacted and potential changes in Medicare and Medicaid reimbursement rates as community hospitals typically generate a significant portion of their revenues and related cash flows from beneficiaries of these programs. In addition to specific account identification, the Company utilizes historical collection experience to establish the allowance for expected credit losses. Financing receivables are written off only after the Company has exhausted all collection efforts. Customer payments are considered past due if a scheduled payment is not received within contractually agreed upon terms. To facilitate customer collection and credit monitoring efforts, financing receivable amounts are invoiced and reclassified to trade accounts receivable when they become due, with all invoiced amounts placed on nonaccrual status. As a result, all past due amounts related to the Company’s financing receivables are included in trade accounts receivable in the accompanying condensed consolidated balance sheets. The following is an analysis of the age of financing receivables amounts (excluding short-term payment plans) that have been reclassified to trade accounts receivable and were past due as of September 30, 2021 and December 31, 2020: (In thousands) 1 to 90 Days Past Due 91 to 180 Days Past Due 181 + Days Past Due Total Past Due September 30, 2021 $ 982 $ 56 $ 148 $ 1,186 December 31, 2020 $ 1,270 $ 227 $ 672 $ 2,169 From time to time, the Company may agree to alternative payment terms outside of the terms of the original financing receivable agreement due to customer difficulties in achieving the original terms. In general, such alternative payment arrangements do not result in a re-aging of the related receivables. Rather, payments pursuant to any alternative payment arrangements are applied to the already outstanding invoices beginning with the oldest outstanding invoices as the payments are received. Because amounts are reclassified to trade accounts receivable when they become due, there are no past due amounts included within financing receivables, current portion, net or financing receivables, net of current portion in the accompanying condensed consolidated balance sheets. The Company utilizes an aging of trade accounts receivable as the primary credit quality indicator for its financing receivables, which is facilitated by the reclassification of customer payment amounts to trade accounts receivable when they become due. The table below categorizes customer financing receivable balances (excluding short-term payment plans) based on the age of the oldest payment outstanding that has been reclassified to trade accounts receivable: (In thousands) September 30, December 31, 2020 Stratification of uninvoiced client financing receivables based on aging of related trade accounts receivable: Uninvoiced client financing receivables related to trade accounts receivable that are 1 to 90 Days Past Due $ 9,797 $ 11,719 Uninvoiced client financing receivables related to trade accounts receivable that are 91 to 180 Days Past Due 680 1,092 Uninvoiced client financing receivables related to trade accounts receivable that are 181 + Days Past Due — 2,668 Total uninvoiced client financing receivables balances of clients with a trade accounts receivable $ 10,477 $ 15,479 Total uninvoiced client financing receivables of clients with no related trade accounts receivable 5,875 6,335 Total financing receivables with contractual maturities of one year or less 225 1,973 Less: allowance for expected credit losses (829) (1,489) Total financing receivables $ 15,748 $ 22,298

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	INTANGIBLE ASSETS AND GOODWILL Our purchased definite-lived intangible assets as of September 30, 2021 and December 31, 2020 are summarized as follows: September 30, 2021 (In thousands) Customer Relationships Trademark Developed Technology Total Gross carrying amount, beginning of period $ 84,370 $ 11,120 $ 29,700 125,190 Intangible assets acquired 28,200 1,200 7,900 37,300 Accumulated amortization (39,534) (4,952) (19,129) (63,615) Net intangible assets as of September 30, 2021 $ 73,036 $ 7,368 $ 18,471 $ 98,875 Weighted average remaining years of useful life 9 13 8 10 December 31, 2020 (In thousands) Customer Relationships Trademark Developed Technology Total Gross carrying amount, beginning of period $ 84,370 $ 11,120 $ 29,700 $ 125,190 Accumulated amortization (33,612) (4,297) (15,592) (53,501) Net intangible assets as of December 31, 2020 $ 50,758 $ 6,823 $ 14,108 $ 71,689 The following table represents the remaining amortization of definite-lived intangible assets as of September 30, 2021: (In thousands) For the year ended December 31, 2021 $ 3,672 2022 14,688 2023 12,800 2024 11,266 2025 10,950 Thereafter 45,499 Total $ 98,875 The following table sets forth the change in the carrying amount of goodwill by segment for the nine months ended September 30, 2021: (In thousands) Acute Care EHR Post-acute Care EHR TruBridge Total Balance as of December 31, 2020 $ 97,095 $ 29,570 $ 23,551 $ 150,216 Goodwill acquired — — 26,980 26,980 Balance as of September 30, 2021 $ 97,095 $ 29,570 $ 50,531 $ 177,196

LONG-TERM DEBT

LONG-TERM DEBT	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT Long-term debt was comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Term loan facility $ 70,312 $ 73,125 Revolving credit facility 46,000 5,000 Debt obligations 116,312 78,125 Less: unamortized debt issuance costs (1,088) (1,308) Debt obligation, net 115,224 76,817 Less: current portion (3,926) (3,457) Long-term debt $ 111,298 $ 73,360 As of September 30, 2021, the carrying value of debt approximated the fair value due to the variable interest rate, which reflected the market rate. Credit Agreement In conjunction with our acquisition of HHI in January 2016, we entered into a syndicated credit agreement with Regions Bank ("Regions") serving as administrative agent, which provided for a $125 million term loan facility and a $50 million revolving credit facility. On June 16, 2020, we entered into an Amended and Restated Credit Agreement that increased the aggregate principal amount of our credit facilities to $185 million, which includes a $75 million term loan facility and a $110 million revolving credit facility. Each of our credit facilities continues to bear interest at a rate per annum equal to an applicable margin plus, at our option, either (1) the Adjusted LIBOR rate for the relevant interest period, subject to a floor of 0.50%, (2) an alternate base rate determined by reference to the greater of (a) the prime lending rate of Regions, (b) the federal funds rate for the relevant interest period plus one half of one percent per annum and (c) the one month LIBOR rate, subject to the aforementioned floor, plus one percent per annum, or (3) a combination of (1) and (2). The applicable margin range for LIBOR loans and the letter of credit fee ranges from 1.8% to 3.0%. The applicable margin range for base rate loans ranges from 0.8% to 2.0%, in each case based on the Company's consolidated net leverage ratio. Principal payments with respect to the term loan facility are due on the last day of each fiscal quarter beginning September 30, 2020, with quarterly principal payments of approximately $0.9 million through June 30, 2022, approximately $1.4 million through June 30, 2024 and approximately $1.9 million through March 31, 2025, with maturity on June 16, 2025 or such earlier date as the obligations under the Amended and Restated Credit Agreement become due and payable pursuant to the terms of such agreement. Any principal outstanding under the revolving credit facility is due and payable on the maturity date. Anticipated annual future maturities of the term loan facility and revolving credit facility are as follows as of September 30, 2021: (In thousands) 2021 $ 936 2022 4,688 2023 5,625 2024 6,563 2025 98,500 Thereafter — $ 116,312 Our credit facilities are secured pursuant to an Amended and Restated Pledge and Security Agreement, dated June 16, 2020, among the parties identified as obligors therein and Regions, as collateral agent, on a first priority basis by a security interest in substantially all of the tangible and intangible assets (subject to certain exceptions) of the Company and certain subsidiaries of the Company, as guarantors (collectively, the “Subsidiary Guarantors”), including certain registered intellectual property and the capital stock of certain of the Company’s direct and indirect subsidiaries. Our obligations under the Amended and Restated Credit Agreement are also guaranteed by the Subsidiary Guarantors. The Amended and Restated Credit Agreement provides incremental facility capacity of $50 million, subject to certain conditions. The Amended and Restated Credit Agreement includes a number of restrictive covenants that, among other things and in each case subject to certain exceptions and baskets, impose operating and financial restrictions on the Company and the Subsidiary Guarantors, including the ability to incur additional debt; incur liens and encumbrances; make certain restricted payments, including paying dividends on the Company's equity securities or payments to redeem, repurchase or retire the Company's equity securities (which are subject to our compliance, on a pro forma basis to give effect to the restricted payment, with the fixed charge coverage ratio and consolidated net leverage ratio described below); enter into certain restrictive agreements; make investments, loans and acquisitions; merge or consolidate with any other person; dispose of assets; enter into sale and leaseback transactions; engage in transactions with affiliates; and materially alter the business we conduct. The Amended and Restated Credit Agreement requires the Company to maintain a minimum fixed charge coverage ratio of 1.25:1.00 throughout the duration of such agreement. Under the Amended and Restated Credit Agreement, the Company is required to comply with a maximum consolidated net leverage ratio of 3.50:1.00. The Amended and Restated Credit Agreement also contains customary representations and warranties, affirmative covenants and events of default. We believe that we were in compliance with the covenants contained in such agreement as of September 30, 2021. The Amended and Restated Credit Agreement requires the Company to mandatorily prepay the credit facilities with 50% of excess cash flow (minus certain specified other payments). This mandatory prepayment requirement is applicable only if the Company's consolidated net leverage ratio exceeds 2.50:1.00. The Company is permitted to voluntarily prepay the credit facilities at any time without penalty, subject to customary “breakage” costs with respect to prepayments of LIBOR rate loans made on a day other than the last day of any applicable interest period. An excess cash flow prepayment related to excess cash flow generated during 2020 was not required during the first quarter of 2021.

OPERATING LEASES

OPERATING LEASES	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
OPERATING LEASES	OPERATING LEASES The Company leases office space in various locations in Alabama, Louisiana, Pennsylvania, Minnesota, Maryland, and Mississippi. These leases have terms expiring from 2021 through 2030 but do contain optional extension terms. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. On July 28,2021, the Company terminated its lease agreement for approximately 45,000 square feet of office space in Fairhope, Alabama. Pursuant to a Termination of Lease Agreement dated July 28, 2021, the Company paid $0.9 million to the landlord as consideration for the early termination. In connection with the lease termination, the Company derecognized the assets and liabilities associated with the operating lease and recorded a $0.3 million loss on the disposal of leasehold improvements. Supplemental balance sheet information related to operating leases was as follows: (In thousands) September 30, Operating lease assets Operating lease assets $ 7,424 Operating lease liabilities Other accrued liabilities $ 1,624 Operating lease liabilities, net of current portion 5,800 Total operating lease liabilities $ 7,424 Weighted average remaining lease term in years 6 Weighted average discount rate 4.6% Because our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We used the incremental borrowing rate on January 1, 2019, for operating leases that commenced prior to that date. The future minimum lease payments payable under these operating leases subsequent to September 30, 2021 are as follows: (In thousands) 2021 $ 409 2022 1,592 2023 1,520 2024 1,411 2025 1,202 Thereafter 2,340 Total lease payments 8,474 Less imputed interest (1,050) Total $ 7,424 Total lease expense for the nine months ended September 30, 2021 and 2020 was $1.4 million and $1.2 million, respectively. Total cash paid for amounts included in the measurement of lease liabilities within operating cash flows from operating leases for the nine months ended September 30, 2021 was $2.3 million.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIESFrom time to time, the Company is involved in routine litigation that arises in the ordinary course of business. Management does not believe it is reasonably possible that such matters will have a material adverse effect on the Company’s financial statements.

FAIR VALUE

FAIR VALUE	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE FASB Codification topic, Fair Value Measurements and Disclosures, establishes a framework for measuring fair value and expands financial statement disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Codification does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. The Codification requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. As of September 30, 2021, we measured the fair value of contingent consideration that represents the potential earnout incentive for TruCode's former equity holders. We estimated the fair value of the contingent consideration based on the probability of TruCode meeting EBITDA targets (subject to certain pro-forma adjustments). We did not have any other instruments that required fair value measurement as of September 30, 2021. The following table summarizes the carrying amounts and fair value of the contingent consideration at September 30, 2021: Fair Value at September 30, 2021 Using Carrying Amount at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (In thousands) 9/30/2021 (Level 1) (Level 2) (Level 3) Description Contingent consideration $ 2,500 $ — $ — $ 2,500 Total $ 2,500 $ — $ — $ 2,500 We did not have any instruments that required fair value measurement at December 31, 2020.

SEGMENT REPORTING

SEGMENT REPORTING	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
SEGMENT REPORTING	SEGMENT REPORTINGOur chief operating decision makers ("CODM") utilize three operating segments, "Acute Care EHR," "Post-acute Care EHR" and "TruBridge," based on our three distinct business units with unique market dynamics and opportunities. Revenues and cost of sales are primarily derived from the provision of services and sales of our proprietary software, and our CODM assess the performance of these three segments at the gross profit level. Operating expenses and items such as interest, income tax, capital expenditures and total assets are managed at a consolidated level and thus are not included in our operating segment disclosures. Our CODM group is comprised of the Chief Executive Officer, Chief Growth Officer, Chief Operating Officer, and Chief Financial Officer. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis. The following table presents a summary of the revenues and gross profits of our three operating segments for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2021 2020 2021 2020 Revenues: Acute Care EHR Recurring revenue $ 26,776 $ 26,421 $ 80,792 $ 78,586 Non-recurring revenue 4,350 9,502 13,786 24,213 Total Acute Care EHR revenue 31,126 35,923 94,578 102,799 Post-acute Care EHR Recurring revenue 4,010 4,026 12,402 12,157 Non-recurring revenue 424 439 913 1,341 Total Post-acute Care EHR revenue 4,434 4,465 13,315 13,498 TruBridge 34,531 27,945 98,736 81,342 Total revenues $ 70,091 $ 68,333 $ 206,629 $ 197,639 Cost of sales: Acute Care EHR $ 16,200 $ 16,488 $ 48,645 $ 48,288 Post-acute Care EHR 1,225 1,140 3,605 3,613 TruBridge 17,377 15,287 50,349 44,100 Total cost of sales $ 34,802 $ 32,915 $ 102,599 $ 96,001 Gross profit: Acute Care EHR $ 14,926 $ 19,435 $ 45,933 $ 54,511 Post-acute Care EHR 3,209 3,325 9,710 9,885 TruBridge 17,154 12,658 48,387 37,242 Total gross profit $ 35,289 $ 35,418 $ 104,030 $ 101,638 Corporate operating expenses $ (30,758) $ (29,214) $ (86,847) $ (86,557) Other income 123 916 1,160 1,241 Loss on extinguishment of debt — — — (202) Interest expense (825) (850) (2,249) (2,832) Income before taxes $ 3,829 $ 6,270 $ 16,094 $ 13,288

COVID-19 PANDEMIC

COVID-19 PANDEMIC	9 Months Ended
	Sep. 30, 2021
Text Block [Abstract]
COVID-19 PANDEMIC	COVID-19 PANDEMIC In December 2019, a novel coronavirus disease (“COVID-19”) was reported and in January 2020, the World Health Organization (“WHO”) declared it a Public Health Emergency of International Concern. In February 2020, the WHO raised its assessment of the COVID-19 threat from high to very high at a global level due to the continued increase in the number of cases and affected countries, and in March 2020, the WHO characterized COVID-19 as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. The COVID-19 pandemic has caused, and is continuing to cause, severe economic, market and other disruptions to the U.S. and global economies. The Company began experiencing adverse business conditions beginning in the latter half of March 2020, which have persisted through the date of this report, including our results of operations for the three and nine months ended September 30, 2021. Most notably: • Travel restrictions and social distancing protocols have created an additional challenge to our on-site implementation and sales teams. Although we have shown success with remote implementation models and our sales representatives are engaging in remote contact with existing customers and prospects, these restrictions and protocols are expected to continue to have an incrementally negative impact on implementation revenues and new sales generation. • Although patient volumes at our client hospitals have largely recovered from the severe declines in such volumes experienced during much of 2020, there can be no guarantee as to the permanence of this recovery. As the overwhelming majority of TruBridge revenues are directly or indirectly correlated with client patient volumes, any further reduction in these patient volumes may negatively impact our related revenues. • Although we have experienced no notable disruption to our operating cash flows through the date of this report, the aforementioned limitations on travel and decreased client patient volumes increase the risk of decreased cash collections from our customers as long as these conditions persist. Such decreases in cash collections could be further negatively impacted by the amount and extent to which the pandemic impacts the financial condition and liquidity of our customers. Despite these adverse business conditions, the pandemic has had a muted impact on our financial condition as of September 30, 2021. However, the ultimate impact of COVID-19 on our operations and financial performance in future periods remains uncertain and will depend on future pandemic related developments, including the duration of the pandemic, any potential subsequent waves of COVID-19 infection, emergence of new variants, the effectiveness, distribution, and acceptance of COVID-19 vaccines, and related government actions to prevent and manage disease spread, all of which are uncertain and cannot be predicted. Consequently, the ongoing pandemic could result in a material impact to the Company’s future financial position, results of operations, cash flows and liquidity.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") and include all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are considered of a normal recurring nature. Quarterly results of operations are not necessarily indicative of annual results. Certain footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2020 was derived from the audited consolidated balance sheet at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of Computer Programs and Systems, Inc. ("CPSI" or the "Company") for the year ended December 31, 2020 and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Internal Use Software	During the second quarter of 2021, we elected to change our method of estimating the labor costs incurred in developing software assets requiring capitalization under Accounting Standards Codification ("ASC") 350-40, Internal Use Software. Prior to this change, we estimated the associated labor costs using an estimated time-equivalent for workload metrics commonly utilized within agile software development environments. With this change, we now estimate these labor costs using the distribution of these agile workload metrics between capitalizable and non-capitalizable units of work. We believe this change is preferable as the new methodology better estimates capitalizable labor costs and is consistent with industry best practices. We have determined that this change is a change in accounting estimate effected by a change in accounting principle and, as such, has been accounted for on a prospective basis. See Note 6, “Software Development,” for further information.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements of CPSI include the accounts of TruBridge, LLC ("TruBridge"), Evident, LLC ("Evident"), Healthland Holding Inc. ("HHI"), iNetXperts, Corp. d/b/a Get Real Health ("Get Real Health"), and TruCode LLC (TruCode), all of which are wholly-owned subsidiaries of CPSI. The accounts of HHI include those of its wholly-owned subsidiaries, Healthland Inc. ("Healthland"), Rycan Technologies, Inc. ("Rycan"), and American HealthTech, Inc. ("AHT"). All significant intercompany balances and transactions have been eliminated.
Recent Account Pronouncements	RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Standards Adopted in 2021 There were no new accounting standards required to be adopted in 2021 that would have a material impact on our consolidated financial statements. New Accounting Standards Yet to be Adopted We do not believe that any other recently issued but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.
Revenue Recognition	Revenue is recognized upon transfer of control of promised products or services to clients in an amount that reflects the consideration we expect to receive in exchange for those products and services. We enter into contracts that can include various combinations of products and services, which are generally distinct and accounted for as separate performance obligations. The Company employs the 5-step revenue recognition model under ASC 606, Revenue from Contracts with Customers , to: (1) identify the contract with the client, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Revenue is recognized net of shipping charges and any taxes collected from clients, which are subsequently remitted to governmental authorities. System Sales and Support The Company enters into contractual obligations to sell perpetual software licenses, installation, conversion, training, hardware and software application support and hardware maintenance services to acute care community hospitals and post-acute care providers. Non-recurring Revenues • Perpetual software licenses, installation, conversion, and related training are not considered separate and distinct performance obligations due to the proprietary nature of our software and are, therefore, accounted for as a single performance obligation on a module-by-module basis. Revenue is recognized as each module's implementation is completed based on the module's stand-alone selling price ("SSP"), net of discounts. Fees for licenses, installation, conversion, and related training are typically due in three installments: (1) at placement of order, (2) upon installation of software and commencement of training, and (3) upon satisfactory completion of monthly accounting cycle or end-of-month operation by application and as applicable for each application. Often, short-term and/or long-term financing arrangements are provided for software implementations; refer to Note 11 - Financing Receivables for further information. Electronic health records ("EHR") implementations include a system warranty that terminates thirty days from the software go-live date, the date on which the client begins using the system in a live environment. • Hardware revenue is recognized separately from software licenses at the point in time it is delivered to the client. The SSP of hardware is cost plus a reasonable margin. Payment is generally due upon delivery of the hardware to the client. Standard manufacturer warranties apply to hardware. Recurring Revenues • Software application support and hardware maintenance services sold with software licenses and hardware are separate and distinct performance obligations. Revenue for support and maintenance services is recognized based on SSP, which is the renewal price, ratably over the life of the contract, which is generally three • Subscriptions to third party content revenue is recognized as a separate performance obligation ratably over the subscription term based on SSP, which is cost plus a reasonable margin. Payment is due monthly for subscriptions to third party content. • Software as a Service ("SaaS") arrangements for EHR software and related conversion and training services are considered a single performance obligation. Revenue is recognized on a monthly basis as the SaaS service is provided to the client over the contract term. Payment is due monthly for SaaS services provided. Refer to Note 17 - Segment Reporting, for further information, including revenue by client base (acute care or post-acute care) bifurcated by recurring and non-recurring revenue. TruBridge TruBridge provides an array of business processing services ("BPS") consisting of accounts receivable management, private pay services, insurance services, medical coding, electronic billing, statement processing, payroll processing, and contract management. Fees are recognized over the period of the client contractual relationship as the services are performed based on the SSP, net of discounts. Fees for many of these services are invoiced, and revenue recognized accordingly, based on the volume of transactions or a percentage of client accounts receivable collections. Payment is due monthly for BPS with certain amounts varying based on utilization and/or volumes. TruBridge also provides professional IT services. Revenue from professional IT services is recognized as the services are performed based on SSP. Payment is due monthly as services are performed. Deferred Revenue Deferred revenue represents amounts invoiced to clients for which the services under contract have not been completed and revenue has not been recognized, including annual renewals of certain software subscriptions and customer deposits for The deferred revenue recorded during the nine months ended September 30, 2021 is comprised primarily of the annual renewals of certain software subscriptions billed during the first quarter of each year and deposits collected for future EHR installations. The deferred revenue recognized as revenue during the nine months ended September 30, 2021 and 2020 is comprised primarily of the periodic recognition of annual renewals that were deferred until earned and deposits for future EHR installations that were deferred until earned. Costs to Obtain and Fulfill a Contract with a Customer Costs to obtain a contract include the commission costs related to SaaS licensing agreements, which are capitalized and amortized ratably over the expected life of the customer. As a practical expedient, we generally recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset would have been one year or less, with the exception of commissions generated from TruBridge sales. TruBridge commissions, which are paid up to twelve months in advance of services performed, are capitalized and amortized over the prepayment period. Costs to obtain a contract are expensed within sales and marketing expenses in the accompanying condensed consolidated statements of income. Contract fulfillment costs related to the implementation of SaaS arrangements are capitalized and amortized ratably over the expected life of the customer. Costs to fulfill contracts consist of the payroll costs for the implementation of SaaS arrangements, including time for training, conversion and installation that is necessary for the software to be utilized. Contract fulfillment costs are expensed within the caption "System sales and support - Cost of sales" in the accompanying condensed consolidated statements of income.
Net Income Per Share	The Company presents basic and diluted earnings per share ("EPS") data for its common stock. Basic EPS is calculated by dividing the net income attributable to stockholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is determined by adjusting the net income attributable to stockholders of the Company and the weighted average number of shares of common stock outstanding during the period for the effects of all dilutive potential common shares, including awards under stock-based compensation arrangements. The Company's unvested restricted stock awards (see Note 10) are considered participating securities under ASC 260, Earnings Per Share , because they entitle holders to non-forfeitable rights to dividends until the awards vest or are forfeited. When a company has a security that qualifies as a "participating security," the Codification requires the use of the two-class method when computing basic EPS. The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net income to allocate to common stockholders, income is allocated to both common stock and participating securities based on their respective weighted average shares outstanding for the period, with net income attributable to common stockholders ultimately equaling net income less net income attributable to participating securities. Diluted EPS for the Company's common stock is computed using the more dilutive of the two-class method or the treasury stock method.
Income Taxes	The Company determines the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment.
Stock-Based Compensation	Stock-based compensation expense is measured at the grant date based on the fair value of the award, and is recognized as an expense over the employee's or non-employee director's requisite service period.
Fair Value	FASB Codification topic, Fair Value Measurements and Disclosures, establishes a framework for measuring fair value and expands financial statement disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Codification does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. The Codification requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data.

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Contract with Customer, Asset and Liability	The following table details deferred revenue for the nine months ended September 30, 2021 and 2020, included in the condensed consolidated balance sheets: (In thousands) Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Beginning balance $ 8,130 $ 8,628 Deferred revenue recorded 16,886 13,633 Deferred revenue acquired 1,300 — Less deferred revenue recognized as revenue (15,472) (14,807) Ending balance $ 10,844 $ 7,454
Schedule of Capitalized Contract Cost	The following table details costs to obtain and fulfill contracts with customers for the nine months ended September 30, 2021 and 2020, included in the condensed consolidated balance sheets: (In thousands) Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Beginning balance $ 5,992 $ 4,440 Costs to obtain and fulfill contracts capitalized 4,719 4,839 Less costs to obtain and fulfill contracts recognized as expense (4,441) (4,044) Ending balance $ 6,270 $ 5,235

BUSINESS COMBINATION (Tables)

BUSINESS COMBINATION (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The preliminary allocation of the purchase price paid for TruCode as of September 30, 2021 was as follows: (In thousands) Purchase Price Allocation Acquired cash $ 4,249 Accounts receivable 924 Prepaid expenses 2 Intangible assets 37,300 Goodwill 26,980 Accounts payable and accrued liabilities (1,772) Contingent consideration (2,500) Deferred revenue (1,300) Net assets acquired $ 63,883
Schedule of Business Acquisition, Pro Forma Information	The following unaudited pro forma revenue, net income and earnings per share amounts for the three and nine months ended September 30, 2021 and 2020 give effect to the TruCode acquisition as if it had been completed on January 1, 2020. The pro forma financial information is presented for illustrative purposes only and is not necessarily indicative of what the operating results actually would have been during the periods presented had the TruCode acquisition been completed during the periods presented. In addition, the unaudited pro forma financial information does not purport to project future operating results. The pro forma information does not fully reflect: (1) any anticipated synergies (or costs to achieve synergies) or (2) the impact of non-recurring items directly related to the TruCode acquisition. Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share data) 2021 2020 2021 2020 Pro forma revenues $ 70,478 $ 71,177 $ 212,449 $ 205,732 Pro forma net income $ 3,115 $ 5,378 $ 15,060 $ 11,181 Pro forma diluted earnings per share $ 0.22 $ 0.37 $ 1.03 $ 0.76

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net was comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Land $ 2,848 $ 2,848 Buildings and improvements 8,269 8,242 Computer equipment 7,863 7,144 Leasehold improvements 783 1,283 Office furniture and fixtures 682 829 Automobiles 18 18 Property and equipment, gross 20,463 20,364 Less: accumulated depreciation (8,363) (7,225) Property and equipment, net $ 12,100 $ 13,139

SOFTWARE DEVELOPMENT (Tables)

SOFTWARE DEVELOPMENT (Tables)	9 Months Ended
	Sep. 30, 2021
Research and Development [Abstract]
Schedule of software development, net	Software development costs, net was comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Software development costs $ 9,774 $ 3,328 Less: accumulated amortization (644) (118) Software development costs, net $ 9,130 $ 3,210

OTHER ACCRUED LIABILITIES (Tabl

OTHER ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities was comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Salaries and benefits $ 7,364 $ 7,876 Severance 506 25 Commissions 875 1,040 Self-insurance reserves 1,730 1,776 Contingent consideration 2,500 — Other 1,646 551 Operating lease liabilities, current portion 1,624 1,518 Other accrued liabilities $ 16,245 $ 12,786

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following is a calculation of the basic and diluted EPS for the Company's common stock, including a reconciliation between net income and net income attributable to common stockholders: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share data) 2021 2020 2021 2020 Net income $ 2,744 $ 5,268 $ 13,029 $ 11,123 Less: Net income attributable to participating securities (59) (151) (293) (338) Net income attributable to common stockholders $ 2,685 $ 5,117 $ 12,736 $ 10,785 Weighted average shares outstanding used in basic per common share computations 14,334 14,095 14,276 14,022 Add: Dilutive potential common shares 9 — 27 — Weighted average shares outstanding used in diluted per common share computations 14,343 14,095 14,303 14,022 Basic EPS $ 0.19 $ 0.36 $ 0.89 $ 0.77 Diluted EPS $ 0.19 $ 0.36 $ 0.89 $ 0.77

STOCK-BASED COMPENSATION AND _2

STOCK-BASED COMPENSATION AND EQUITY (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Total Stock-Based Compensation Expense	The following table details total stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020, included in the condensed consolidated statements of income: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2021 2020 2021 2020 Costs of sales $ 311 $ 321 $ 793 $ 1,100 Operating expenses 1,389 1,243 3,386 4,074 Pre-tax stock-based compensation expense 1,700 1,564 4,179 5,174 Less: income tax effect (374) (344) (919) (1,138) Net stock-based compensation expense $ 1,326 $ 1,220 $ 3,260 $ 4,036
Summary of Restricted Stock Activity	A summary of restricted stock activity (including shares of restricted stock issued pursuant to the settlement of performance share awards) under the Plans during the nine months ended September 30, 2021 and 2020 is as follows: Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Shares Weighted-Average Shares Weighted-Average Unvested restricted stock outstanding at beginning of period 412,967 $ 28.87 525,859 $ 30.51 Granted 153,700 31.22 136,771 26.16 Performance share awards settled through the issuance of restricted stock — — 19,678 30.15 Vested (245,455) 29.16 (265,518) 30.85 Forfeited (6,329) 29.10 — — Unvested restricted stock outstanding at end of period 314,883 $ 29.79 416,790 $ 28.85
Summary of Performance Share Award Activity	A summary of performance share award activity under the Plans during the nine months ended September 30, 2021 and 2020 is as follows, based on the target award amounts set forth in the performance share award agreements: Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Shares Weighted-Average Shares Weighted-Average Performance share awards outstanding at beginning of period 252,852 $ 29.27 200,709 $ 30.75 Granted 93,444 31.26 107,298 26.96 Adjusted for actual performance, net of forfeitures (20,373) 29.92 (35,477) 30.15 Performance share awards settled through the issuance of restricted stock — — (19,678) 30.15 Vested (75,971) 30.50 — — Performance share awards outstanding at end of period 249,952 $ 29.59 252,852 $ 29.27

FINANCING RECEIVABLES (Tables)

FINANCING RECEIVABLES (Tables)	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Schedule of Components of Short Term Payment Plans	These receivables, included in the current portion of financing receivables, were comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Short-term payment plans, gross $ 225 $ 1,973 Less: allowance for losses (11) (99) Short-term payment plans, net $ 214 $ 1,874
Components of Lease Receivables	The components of these receivables were as follows at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Long-term financing arrangements, gross $ 17,952 $ 24,082 Less: allowance for expected credit losses (818) (1,390) Less: unearned income (1,600) (2,268) Long-term financing arrangements, net $ 15,534 $ 20,424
Future Minimum Lease Payments to be Received	Future minimum payments to be received subsequent to September 30, 2021 are as follows: (In thousands) Years Ending December 31, 2021 $ 4,542 2022 6,013 2023 3,924 2024 2,393 2025 948 Thereafter 132 Total minimum payments to be received 17,952 Less: allowance for expected credit losses (818) Less: unearned income (1,600) Receivables, net $ 15,534
Allowance for Financing Credit Losses	The following table is a roll-forward of the allowance for expected credit losses for the nine months ended September 30, 2021 and year ended December 31, 2020: (In thousands) Balance at Beginning of Period Provision Charge-offs Recoveries Balance at End of Period September 30, 2021 $ 1,489 $ 588 $ (1,248) $ — $ 829 December 31, 2020 $ 2,971 $ 1,632 $ (3,114) $ — $ 1,489
Analysis of Age of Financing Receivables Amounts	The following is an analysis of the age of financing receivables amounts (excluding short-term payment plans) that have been reclassified to trade accounts receivable and were past due as of September 30, 2021 and December 31, 2020: (In thousands) 1 to 90 Days Past Due 91 to 180 Days Past Due 181 + Days Past Due Total Past Due September 30, 2021 $ 982 $ 56 $ 148 $ 1,186 December 31, 2020 $ 1,270 $ 227 $ 672 $ 2,169
Schedule of Financing Receivable Credit Quality Indicators	The table below categorizes customer financing receivable balances (excluding short-term payment plans) based on the age of the oldest payment outstanding that has been reclassified to trade accounts receivable: (In thousands) September 30, December 31, 2020 Stratification of uninvoiced client financing receivables based on aging of related trade accounts receivable: Uninvoiced client financing receivables related to trade accounts receivable that are 1 to 90 Days Past Due $ 9,797 $ 11,719 Uninvoiced client financing receivables related to trade accounts receivable that are 91 to 180 Days Past Due 680 1,092 Uninvoiced client financing receivables related to trade accounts receivable that are 181 + Days Past Due — 2,668 Total uninvoiced client financing receivables balances of clients with a trade accounts receivable $ 10,477 $ 15,479 Total uninvoiced client financing receivables of clients with no related trade accounts receivable 5,875 6,335 Total financing receivables with contractual maturities of one year or less 225 1,973 Less: allowance for expected credit losses (829) (1,489) Total financing receivables $ 15,748 $ 22,298

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Definite-lived Intangible Assets	Our purchased definite-lived intangible assets as of September 30, 2021 and December 31, 2020 are summarized as follows: September 30, 2021 (In thousands) Customer Relationships Trademark Developed Technology Total Gross carrying amount, beginning of period $ 84,370 $ 11,120 $ 29,700 125,190 Intangible assets acquired 28,200 1,200 7,900 37,300 Accumulated amortization (39,534) (4,952) (19,129) (63,615) Net intangible assets as of September 30, 2021 $ 73,036 $ 7,368 $ 18,471 $ 98,875 Weighted average remaining years of useful life 9 13 8 10 December 31, 2020 (In thousands) Customer Relationships Trademark Developed Technology Total Gross carrying amount, beginning of period $ 84,370 $ 11,120 $ 29,700 $ 125,190 Accumulated amortization (33,612) (4,297) (15,592) (53,501) Net intangible assets as of December 31, 2020 $ 50,758 $ 6,823 $ 14,108 $ 71,689
Schedule of Remaining Amortization of Definite-lived Intangible Assets	The following table represents the remaining amortization of definite-lived intangible assets as of September 30, 2021: (In thousands) For the year ended December 31, 2021 $ 3,672 2022 14,688 2023 12,800 2024 11,266 2025 10,950 Thereafter 45,499 Total $ 98,875
Schedule of Changes in the Carrying Amount of Goodwill	The following table sets forth the change in the carrying amount of goodwill by segment for the nine months ended September 30, 2021: (In thousands) Acute Care EHR Post-acute Care EHR TruBridge Total Balance as of December 31, 2020 $ 97,095 $ 29,570 $ 23,551 $ 150,216 Goodwill acquired — — 26,980 26,980 Balance as of September 30, 2021 $ 97,095 $ 29,570 $ 50,531 $ 177,196

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt was comprised of the following at September 30, 2021 and December 31, 2020: (In thousands) September 30, December 31, 2020 Term loan facility $ 70,312 $ 73,125 Revolving credit facility 46,000 5,000 Debt obligations 116,312 78,125 Less: unamortized debt issuance costs (1,088) (1,308) Debt obligation, net 115,224 76,817 Less: current portion (3,926) (3,457) Long-term debt $ 111,298 $ 73,360
Schedule of Annual Future Maturities of the Term Loan Facility and Revolving Credit Facility	Anticipated annual future maturities of the term loan facility and revolving credit facility are as follows as of September 30, 2021: (In thousands) 2021 $ 936 2022 4,688 2023 5,625 2024 6,563 2025 98,500 Thereafter — $ 116,312

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Schedule of Lease, Supplemental Balance Sheet Information	Supplemental balance sheet information related to operating leases was as follows: (In thousands) September 30, Operating lease assets Operating lease assets $ 7,424 Operating lease liabilities Other accrued liabilities $ 1,624 Operating lease liabilities, net of current portion 5,800 Total operating lease liabilities $ 7,424 Weighted average remaining lease term in years 6 Weighted average discount rate 4.6%
Schedule of Operating Lease, Liability, Maturity	The future minimum lease payments payable under these operating leases subsequent to September 30, 2021 are as follows: (In thousands) 2021 $ 409 2022 1,592 2023 1,520 2024 1,411 2025 1,202 Thereafter 2,340 Total lease payments 8,474 Less imputed interest (1,050) Total $ 7,424

FAIR VALUE (Tables)

FAIR VALUE (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Carrying Amounts and Fair Value of the Contingent Consideration	The following table summarizes the carrying amounts and fair value of the contingent consideration at September 30, 2021: Fair Value at September 30, 2021 Using Carrying Amount at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (In thousands) 9/30/2021 (Level 1) (Level 2) (Level 3) Description Contingent consideration $ 2,500 $ — $ — $ 2,500 Total $ 2,500 $ — $ — $ 2,500

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents a summary of the revenues and gross profits of our three operating segments for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2021 2020 2021 2020 Revenues: Acute Care EHR Recurring revenue $ 26,776 $ 26,421 $ 80,792 $ 78,586 Non-recurring revenue 4,350 9,502 13,786 24,213 Total Acute Care EHR revenue 31,126 35,923 94,578 102,799 Post-acute Care EHR Recurring revenue 4,010 4,026 12,402 12,157 Non-recurring revenue 424 439 913 1,341 Total Post-acute Care EHR revenue 4,434 4,465 13,315 13,498 TruBridge 34,531 27,945 98,736 81,342 Total revenues $ 70,091 $ 68,333 $ 206,629 $ 197,639 Cost of sales: Acute Care EHR $ 16,200 $ 16,488 $ 48,645 $ 48,288 Post-acute Care EHR 1,225 1,140 3,605 3,613 TruBridge 17,377 15,287 50,349 44,100 Total cost of sales $ 34,802 $ 32,915 $ 102,599 $ 96,001 Gross profit: Acute Care EHR $ 14,926 $ 19,435 $ 45,933 $ 54,511 Post-acute Care EHR 3,209 3,325 9,710 9,885 TruBridge 17,154 12,658 48,387 37,242 Total gross profit $ 35,289 $ 35,418 $ 104,030 $ 101,638 Corporate operating expenses $ (30,758) $ (29,214) $ (86,847) $ (86,557) Other income 123 916 1,160 1,241 Loss on extinguishment of debt — — — (202) Interest expense (825) (850) (2,249) (2,832) Income before taxes $ 3,829 $ 6,270 $ 16,094 $ 13,288

REVENUE RECOGNITION (Detail)

REVENUE RECOGNITION (Detail)	9 Months Ended
	Sep. 30, 2021
Minimum
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Maintenance contract term	3 years
Maximum
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Maintenance contract term	5 years

REVENUE RECOGNITION Deferred Re

REVENUE RECOGNITION Deferred Revenue (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Change in Contract with Customer, Liability [Roll Forward]
Beginning balance	$ 8,130	$ 8,628
Deferred revenue recorded	16,886	13,633
Deferred revenue acquired	1,300	0
Less deferred revenue recognized as revenue	(15,472)	(14,807)
Ending balance	$ 10,844	$ 7,454

REVENUE RECOGNITION Costs to ob

REVENUE RECOGNITION Costs to obtain and fulfill contracts (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Capitalized Contract Cost [Roll Forward]
Beginning balance	$ 5,992	$ 4,440
Costs to obtain and fulfill contracts capitalized	4,719	4,839
Less costs to obtain and fulfill contracts recognized as expense	(4,441)	(4,044)
Ending balance	$ 6,270	$ 5,235

BUSINESS COMBINATION - Narrativ

BUSINESS COMBINATION - Narrative (Details) - TruCode, LLC - USD ($) $ in Millions	May 12, 2021	Sep. 30, 2021	Sep. 30, 2021
Business Acquisition [Line Items]
Consideration transferred	$ 59.6
Contingent consideration earnout payment (up to)	$ 15
Business combination, contingent consideration period	12 months
Acquisition related costs			$ 0.9
Pro forma information, revenue		$ 2.6	4.1
Pro forma information, pre-tax income		$ 1.4	$ 1.8

BUSINESS COMBINATION - Prelimin

BUSINESS COMBINATION - Preliminary allocation of the purchase price paid (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 177,196	$ 150,216
TruCode, LLC
Business Acquisition [Line Items]
Acquired cash	4,249
Accounts receivable	924
Prepaid expenses	2
Intangible assets	37,300
Goodwill	26,980
Accounts payable and accrued liabilities	(1,772)
Contingent consideration	(2,500)
Deferred revenue	(1,300)
Net assets acquired	$ 63,883

BUSINESS COMBINATION - Pro form

BUSINESS COMBINATION - Pro forma information (Details) - TruCode, LLC - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Pro forma revenues	$ 70,478	$ 71,177	$ 212,449	$ 205,732
Pro forma net income	$ 3,115	$ 5,378	$ 15,060	$ 11,181
Pro forma diluted earnings per share (in dollars per share)	$ 0.22	$ 0.37	$ 1.03	$ 0.76

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 20,463	$ 20,364
Less: accumulated depreciation	(8,363)	(7,225)
Property and equipment, net	12,100	13,139
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,848	2,848
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,269	8,242
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,863	7,144
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	783	1,283
Office furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	682	829
Automobiles
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 18	$ 18

SOFTWARE DEVELOPMENT - Schedule

SOFTWARE DEVELOPMENT - Schedule of Software development costs, net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Research and Development [Abstract]
Software development costs	$ 9,774	$ 3,328
Less: accumulated amortization	(644)	(118)
Software development costs, net	$ 9,130	$ 3,210

SOFTWARE DEVELOPMENT - Narrativ

SOFTWARE DEVELOPMENT - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Capitalized software development costs	$ 2.4	$ 6.5
Increase in capitalized software development costs	$ 1.1	$ 3
Software Development
Finite-Lived Intangible Assets [Line Items]
Estimated useful life		5 years

OTHER ACCRUED LIABILITIES (Deta

OTHER ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Salaries and benefits	$ 7,364	$ 7,876
Severance	506	25
Commissions	875	1,040
Self-insurance reserves	1,730	1,776
Contingent consideration	2,500	0
Other	1,646	551
Operating lease liabilities, current portion	1,624	1,518
Other accrued liabilities	$ 16,245	$ 12,786

NET INCOME PER SHARE (Details)

NET INCOME PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share, Basic and Diluted [Abstract]
Net income	$ 2,744	$ 5,268	$ 13,029	$ 11,123
Less: Net income attributable to participating securities	(59)	(151)	(293)	(338)
Net income attributable to common stockholders	$ 2,685	$ 5,117	$ 12,736	$ 10,785
Weighted average shares outstanding used in basic per common share computations (in shares)	14,334,000	14,095,000	14,276,000	14,022,000
Add: Dilutive potential common shares (in shares)	8,897	0	26,601	0
Weighted average shares outstanding used in diluted per common share computations (in shares)	14,343,000	14,095,000	14,303,000	14,022,000
Basic EPS (in dollars per share)	$ 0.19	$ 0.36	$ 0.89	$ 0.77
Diluted EPS (in dollars per share)	$ 0.19	$ 0.36	$ 0.89	$ 0.77

NET INCOME PER SHARE Narrative

NET INCOME PER SHARE Narrative (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Aggregate target (in shares)			249,952
Dilutive potential common shares included in the calculation of diluted earnings per share (in shares)	8,897	0	26,601	0

INCOME TAXES (Details)

INCOME TAXES (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Effective tax rate percentage	28.30%	16.00%	19.00%	16.30%
Periodic provision-to-return adjustments, percent	6.10%	3.70%

STOCK-BASED COMPENSATION AND _3

STOCK-BASED COMPENSATION AND EQUITY - Total Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Pre-tax stock-based compensation expense	$ 1,700	$ 1,564	$ 4,179	$ 5,174
Less: income tax effect	(374)	(344)	(919)	(1,138)
Net stock-based compensation expense	1,326	1,220	3,260	4,036
Unrecognized compensation cost related to non-vested stock-based compensation arrangements	9,000		$ 9,000
Period for recognition for which unrecognized compensation costs are expected to be recognized			2 years 1 month 6 days
Costs of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Pre-tax stock-based compensation expense	311	321	$ 793	1,100
Operating expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Pre-tax stock-based compensation expense	$ 1,389	$ 1,243	$ 3,386	$ 4,074

STOCK-BASED COMPENSATION AND _4

STOCK-BASED COMPENSATION AND EQUITY - Summary of Restricted Stock Activity (Details) - Restricted Stock - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Shares
Stock outstanding at beginning of period, shares	412,967	525,859
Granted, shares	153,700	136,771
Performance share awards settled through issuance of restricted stock, shares	0	19,678
Vested, shares	(245,455)	(265,518)
Forfeited, shares	(6,329)	0
Stock outstanding at end of period, shares	314,883	416,790
Weighted-Average Grant Date Fair Value Per Share
Nonvested stock outstanding at beginning of period, Weighted-Average Grant-Date Fair Value (in dollars per share)	$ 28.87	$ 30.51
Granted, Weighted-Average Grant-Date Fair Value (in dollars per share)	31.22	26.16
Settled, Weighted-Average Grant-Date Fair Value (in dollars per share)	0	30.15
Vested, Weighted-Average Grant-Date Fair Value (in dollars per share)	29.16	30.85
Forfeited, Weighted-Average Grant-Date Fair Value (in dollars per share)	29.10	0
Nonvested stock outstanding at end of period, Weighted-Average Grant-Date Fair Value (in dollars per share)	$ 29.79	$ 28.85
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years

STOCK-BASED COMPENSATION AND _5

STOCK-BASED COMPENSATION AND EQUITY - Summary of Performance Share Awards (Details) - Performance Shares - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Shares
Stock outstanding at beginning of period, shares	252,852	200,709
Granted, shares	93,444	107,298
Adjusted for actual performance, net of forfeitures, shares	(20,373)	(35,477)
Performance share awards settled through issuance of restricted stock, shares		(19,678)
Vested, shares	(75,971)
Stock outstanding at end of period, shares	249,952	252,852
Weighted-Average Grant Date Fair Value Per Share
Nonvested stock outstanding at beginning of period, Weighted-Average Grant-Date Fair Value (in dollars per share)	$ 29.27	$ 30.75
Granted, Weighted-Average Grant-Date Fair Value (in dollars per share)	31.26	26.96
Actual performance, net of forfeitures, Weighted-Average Grant Date Fair Value (in dollars per share)	29.92	30.15
Settled, Weighted-Average Grant-Date Fair Value (in dollars per share)		30.15
Vested, Weighted-Average Grant-Date Fair Value (in dollars per share)	30.50
Nonvested stock outstanding at end of period, Weighted-Average Grant-Date Fair Value (in dollars per share)	$ 29.59	$ 29.27
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years

STOCK-BASED COMPENSATION AND _6

STOCK-BASED COMPENSATION AND EQUITY - Stock Repurchases (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 04, 2020
Share-based Payment Arrangement [Abstract]
Stock repurchase program, authorized amount			$ 30,000,000
Stock repurchased during period (in shares)	17,387	0
Stock repurchase program, remaining authorized repurchase amount	$ 28,200,000
Shares purchased for award (in shares)	21,444

FINANCING RECEIVABLES - Narrati

FINANCING RECEIVABLES - Narrative (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2016
Loans and Leases Receivable Disclosure [Line Items]
New acute care EHR customer installations, percentage			75.00%
Percentage of customer license preference has shifted dramatically towards SaaS arrangements	60.00%	70.00%
Minimum
Loans and Leases Receivable Disclosure [Line Items]
Financial receivable lease term	2 years
Maximum
Loans and Leases Receivable Disclosure [Line Items]
Financial receivable lease term	7 years
Fixed Periodic Payment Plans | Minimum
Loans and Leases Receivable Disclosure [Line Items]
Current financing receivable terms	3 months
Fixed Periodic Payment Plans | Maximum
Loans and Leases Receivable Disclosure [Line Items]
Current financing receivable terms	12 months

FINANCING RECEIVABLES - Short t

FINANCING RECEIVABLES - Short term Payment Plans (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Financing Receivable, Allowance for Credit Loss [Line Items]
Less: allowance for losses	$ (364)	$ (541)
Short-term payment plans, net	7,277	10,821
Short-Term Payment Plans
Financing Receivable, Allowance for Credit Loss [Line Items]
Short-term payment plans, gross	225	1,973
Less: allowance for losses	(11)	(99)
Short-term payment plans, net	$ 214	$ 1,874

FINANCING RECEIVABLES - Compone

FINANCING RECEIVABLES - Components of Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Financing Receivable, Recorded Investment, Past Due [Line Items]
Less: allowance for expected credit losses	$ (829)	$ (1,489)	$ (2,971)
Total financing receivables	15,748	22,298
Long-Term Financing Arrangement
Financing Receivable, Recorded Investment, Past Due [Line Items]
Long-term financing arrangements, gross	17,952	24,082
Less: allowance for expected credit losses	(818)	(1,390)
Less: unearned income	(1,600)	(2,268)
Total financing receivables	$ 15,534	$ 20,424

FINANCING RECEIVABLES - Future

FINANCING RECEIVABLES - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Financing Receivable, Recorded Investment, Past Due [Line Items]
Less: allowance for expected credit losses	$ (829)	$ (1,489)	$ (2,971)
Total financing receivables	15,748	22,298
Long-Term Financing Arrangement
Financing Receivable, Recorded Investment, Past Due [Line Items]
2021	4,542
2022	6,013
2023	3,924
2024	2,393
2025	948
Thereafter	132
Total minimum payments to be received	17,952
Less: allowance for expected credit losses	(818)	(1,390)
Less: unearned income	(1,600)	(2,268)
Total financing receivables	$ 15,534	$ 20,424

FINANCING RECEIVABLES - Allowan

FINANCING RECEIVABLES - Allowance for Financing Credit Losses (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Allowance for Credit Losses on Financing Receivables [Roll Forward]
Balance at Beginning of Period	$ 1,489	$ 2,971
Provision	588	1,632
Charge-offs	(1,248)	(3,114)
Recoveries	0	0
Balance at End of Period	$ 829	$ 1,489

FINANCING RECEIVABLES - Analysi

FINANCING RECEIVABLES - Analysis of Age of Financing Receivables Amounts (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Total Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Long-term financing arrangements, gross	$ 1,186	$ 2,169
1 to 90 Days Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Long-term financing arrangements, gross	982	1,270
91 to 180 Days Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Long-term financing arrangements, gross	56	227
181 + Days Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Long-term financing arrangements, gross	$ 148	$ 672

FINANCING RECEIVABLES - Summary

FINANCING RECEIVABLES - Summary of Financing Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total financing receivables with contractual maturities of one year or less	$ 225	$ 1,973
Less: allowance for expected credit losses	(829)	(1,489)	$ (2,971)
Total financing receivables	15,748	22,298
Total Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	1,186	2,169
Total Past Due | Trade Accounts Receivable
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	10,477	15,479
Uninvoiced client financing receivables related to trade accounts receivable that are 1 to 90 Days Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	982	1,270
Uninvoiced client financing receivables related to trade accounts receivable that are 1 to 90 Days Past Due | Trade Accounts Receivable
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	9,797	11,719
Uninvoiced client financing receivables related to trade accounts receivable that are 91 to 180 Days Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	56	227
Uninvoiced client financing receivables related to trade accounts receivable that are 91 to 180 Days Past Due | Trade Accounts Receivable
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	680	1,092
Uninvoiced client financing receivables related to trade accounts receivable that are 181 + Days Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	148	672
Uninvoiced client financing receivables related to trade accounts receivable that are 181 + Days Past Due | Trade Accounts Receivable
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	0	2,668
Total Not Past Due
Financing Receivable, Recorded Investment, Past Due [Line Items]
Total uninvoiced client financing receivables of clients with no related trade accounts receivable	$ 5,875	$ 6,335

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL - Definite-lived Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount, beginning of period		$ 125,190	$ 125,190
Intangible assets acquired	$ 37,300
Accumulated amortization	(63,615)	(53,501)
Intangible assets, net	$ 98,875	71,689
Weighted average remaining years of useful life	10 years
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount, beginning of period		84,370	84,370
Intangible assets acquired	$ 28,200
Accumulated amortization	(39,534)	(33,612)
Intangible assets, net	$ 73,036	50,758
Weighted average remaining years of useful life	9 years
Trademark
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount, beginning of period		11,120	11,120
Intangible assets acquired	$ 1,200
Accumulated amortization	(4,952)	(4,297)
Intangible assets, net	$ 7,368	6,823
Weighted average remaining years of useful life	13 years
Developed Technology
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount, beginning of period		29,700	$ 29,700
Intangible assets acquired	$ 7,900
Accumulated amortization	(19,129)	(15,592)
Intangible assets, net	$ 18,471	$ 14,108
Weighted average remaining years of useful life	8 years

INTANGIBLE ASSETS AND GOODWIL_3

INTANGIBLE ASSETS AND GOODWILL - Remaining Amortization of Definite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 3,672
2022	14,688
2023	12,800
2024	11,266
2025	10,950
Thereafter	45,499
Intangible assets, net	$ 98,875	$ 71,689

INTANGIBLE ASSETS AND GOODWIL_4

INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 150,216
Goodwill acquired	26,980
Goodwill, ending balance	177,196
Operating Segments | Acute Care EHR
Goodwill [Roll Forward]
Goodwill, beginning balance	97,095
Goodwill acquired	0
Goodwill, ending balance	97,095
Operating Segments | Post-acute Care EHR
Goodwill [Roll Forward]
Goodwill, beginning balance	29,570
Goodwill acquired	0
Goodwill, ending balance	29,570
Operating Segments | TruBridge
Goodwill [Roll Forward]
Goodwill, beginning balance	23,551
Goodwill acquired	26,980
Goodwill, ending balance	$ 50,531

LONG-TERM DEBT - Schedule of lo

LONG-TERM DEBT - Schedule of long-term debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt obligations	$ 116,312	$ 78,125
Less: unamortized debt issuance costs	(1,088)	(1,308)
Debt obligation, net	115,224	76,817
Less: current portion	(3,926)	(3,457)
Long-term debt	111,298	73,360
Line of credit | Term loan facility
Debt Instrument [Line Items]
Debt obligations	70,312	73,125
Line of credit | Revolving credit facility
Debt Instrument [Line Items]
Debt obligations	$ 46,000	$ 5,000

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - Line of credit - USD ($)	Jun. 16, 2020	Jan. 31, 2016	Jun. 30, 2022	Jun. 30, 2024	Mar. 31, 2025
Debt Instrument [Line Items]
Line of credit facility, incremental facility capacity	$ 50,000,000
Fixed charge coverage ratio, minimum	1.25
Consolidated leverage ratio, maximum	3.5
Prepayment amount from excess cash flow, year two and thereafter, percentage	50.00%
Consolidated leverage ratio	2.5
London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
Term loan facility
Debt Instrument [Line Items]
Amount of credit facility	$ 75,000,000	$ 125,000,000
Term loan facility | Forecast
Debt Instrument [Line Items]
Periodic payment, principal			$ 900,000	$ 1,400,000	$ 1,900,000
Revolving credit facility
Debt Instrument [Line Items]
Amount of credit facility	$ 110,000,000	$ 50,000,000
Revolving credit facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Revolving credit facility | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.80%
Revolving credit facility | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	3.00%
Revolving credit facility | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.80%
Revolving credit facility | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.00%
Revolving credit facility | Federal funds rate
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Amended and restated credit agreement
Debt Instrument [Line Items]
Amount of credit facility	$ 185,000,000

LONG-TERM DEBT - Annual Future

LONG-TERM DEBT - Annual Future Maturities (Details) - Line of credit $ in Thousands	Sep. 30, 2021USD ($)
Debt Instrument [Line Items]
2021	$ 936
2022	4,688
2023	5,625
2024	6,563
2025	98,500
Thereafter	0
Long-term Debt, Total	$ 116,312

OPERATING LEASES - Supplemental

OPERATING LEASES - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease assets	$ 7,424	$ 6,610
Other accrued liabilities	1,624	1,518
Operating lease liabilities, net of current portion	5,800	$ 5,092
Total operating lease liabilities	$ 7,424
Weighted average remaining lease term in years	6 years
Weighted average discount rate	4.60%

OPERATING LEASES - Future Minim

OPERATING LEASES - Future Minimum Lease Payments Payable Under these Operating Leases (Details) $ in Thousands	Sep. 30, 2021USD ($)
Leases [Abstract]
2021	$ 409
2022	1,592
2023	1,520
2024	1,411
2025	1,202
Thereafter	2,340
Total lease payments	8,474
Less imputed interest	(1,050)
Total	$ 7,424

OPERATING LEASES - Narrative (D

OPERATING LEASES - Narrative (Details) $ in Millions	Jul. 28, 2021USD ($)ft²	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Leases [Abstract]
Area of real estate property | ft²	45,000
Payments on early termination of lease	$ 0.9
Loss on termination of lease		$ 0.3
Lease expense		1.4	$ 1.2
Operating lease, payments		$ 2.3

FAIR VALUE (Details)

FAIR VALUE (Details) - Fair Value, Recurring $ in Thousands	Sep. 30, 2021USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 2,500
Total financial liabilities	2,500
(Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Total financial liabilities	0
(Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Total financial liabilities	0
(Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	2,500
Total financial liabilities	$ 2,500

SEGMENT REPORTING (Details)

SEGMENT REPORTING (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)segment	Sep. 30, 2020USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | segment			3
Total sales revenues	$ 70,091	$ 68,333	$ 206,629	$ 197,639
Costs to obtain and fulfill contracts capitalized	34,802	32,915	102,599	96,001
Total gross profit	35,289	35,418	104,030	101,638
Corporate operating expenses	(30,758)	(29,214)	(86,847)	(86,557)
Other income	123	916	1,160	1,241
Loss on extinguishment of debt	0	0	0	(202)
Interest expense	(825)	(850)	(2,249)	(2,832)
Income before taxes	3,829	6,270	16,094	13,288
Operating Segments | Acute Care EHR
Segment Reporting Information [Line Items]
Total sales revenues	31,126	35,923	94,578	102,799
Costs to obtain and fulfill contracts capitalized	16,200	16,488	48,645	48,288
Total gross profit	14,926	19,435	45,933	54,511
Operating Segments | Post-acute Care EHR
Segment Reporting Information [Line Items]
Total sales revenues	4,434	4,465	13,315	13,498
Costs to obtain and fulfill contracts capitalized	1,225	1,140	3,605	3,613
Total gross profit	3,209	3,325	9,710	9,885
Operating Segments | TruBridge
Segment Reporting Information [Line Items]
Total sales revenues	34,531	27,945	98,736	81,342
Costs to obtain and fulfill contracts capitalized	17,377	15,287	50,349	44,100
Total gross profit	17,154	12,658	48,387	37,242
Corporate operating expenses
Segment Reporting Information [Line Items]
Corporate operating expenses	(30,758)	(29,214)	(86,847)	(86,557)
Recurring revenue | Operating Segments | Acute Care EHR
Segment Reporting Information [Line Items]
Total sales revenues	26,776	26,421	80,792	78,586
Recurring revenue | Operating Segments | Post-acute Care EHR
Segment Reporting Information [Line Items]
Total sales revenues	4,010	4,026	12,402	12,157
Non-recurring revenue | Operating Segments | Acute Care EHR
Segment Reporting Information [Line Items]
Total sales revenues	4,350	9,502	13,786	24,213
Non-recurring revenue | Operating Segments | Post-acute Care EHR
Segment Reporting Information [Line Items]
Total sales revenues	$ 424	$ 439	$ 913	$ 1,341